FDA Orange Book
Is there a generic for Inbrija?
Inbrija contains levodopa. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Inbrija (levodopa). The Orange Book shows its last listed patent expires October 21, 2033.
Run it in Rivvi
Map Inbrija and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Inbrija products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| powder, inhalation | 42MG | Marketed (Rx) | None | 0 | None |
NDA 209184, held by MERZ PHARMACEUTICALS LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Inbrija patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| RE43711 | February 3, 2029 | Method of use | U-2484 | 209184 |
| 8685442 | November 16, 2032 | Drug product | None | 209184 |
| 8945612 | November 16, 2032 | Drug product | None | 209184 |
| 8545878 | November 16, 2032 | Drug product | None | 209184 |
| 9393210 | November 16, 2032 | Drug product | None | 209184 |
| 12458615 | October 21, 2033 | Method of use | U-2484 | 209184 |
Inbrija NDC codes
Questions
Is there a generic for Inbrija?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Inbrija (levodopa). The Orange Book shows its last listed patent expires October 21, 2033.
What is the generic name for Inbrija?
The active ingredient in Inbrija is levodopa, per the FDA Orange Book.
When does the Inbrija patent expire?
The last patent listed for Inbrija in the Orange Book expires October 21, 2033. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.